Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell-depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent...
Overview
Authors
Affiliations
Serious infections are a major obstacle limiting the usefulness of unrelated donor marrow transplantation. Graft-versus-host disease (GVHD) and its therapy are associated with a high risk of opportunistic infection. In this study, patients were randomized to receive 1 of 2 GVHD prophylaxis strategies, marrow T cell depletion, and cyclosporine (TCD) or methotrexate/cyclosporine (M/C) after transplantation. The patients underwent transplantation between March 1995 and October 2000 as part of a multicenter randomized trial. As a secondary analysis, we analyzed infections in this study cohort. Among the 404 patients who underwent transplantation, a total of 1598 infections were reported. The rates of serious and fatal infections did not differ between the TCD and M/C groups. Bacterial infections accounted for 1/3 of serious infections in each treatment arm. A significantly higher incidence of severe cytomegalovirus (CMV) and life-threatening or fatal aspergillus infections was observed in the patients receiving TCD (CMV, 28% vs 17% [P = .02]; aspergillosis, 16% vs 7% [P < .01]). The only independent risk factor for serious infection was the development of grade III-IV acute GVHD (aGVHD; hazard ratio = 1.41; 95% confidence interval = 1.03-1.91). Strategies to speed immune recovery, even in the absence of GVHD, are needed to overcome the risk of infection after unrelated donor transplantation.
Xu J, Zhang H, Zhao Y, Zhang X, Guo S, Shi X Cancer Immunol Immunother. 2025; 74(5):149.
PMID: 40088283 DOI: 10.1007/s00262-025-03998-1.
Daily Fungal Cell-Free DNA Testing to Assess Clinical Status during Fungemia.
Young J, Liu X, Porter E, Sweet H, Wang W, Evans A J Fungi (Basel). 2024; 10(7).
PMID: 39057334 PMC: 11278359. DOI: 10.3390/jof10070449.
Morrissey C, Kim H, Duong T, Moran E, Alastruey-Izquierdo A, Denning D Med Mycol. 2024; 62(6).
PMID: 38935907 PMC: 11210617. DOI: 10.1093/mmy/myad129.
Shahid Z, Etra A, Levine J, Riches M, Baluch A, Hill J Transplant Cell Ther. 2024; 30(5):540.e1-540.e13.
PMID: 38458478 PMC: 11217895. DOI: 10.1016/j.jtct.2024.03.001.
Li X, Yang J, Cai Y, Huang C, Xu X, Qiu H Front Immunol. 2023; 14:1252879.
PMID: 37954615 PMC: 10639171. DOI: 10.3389/fimmu.2023.1252879.